Chimeric microRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 1129-1136

  Li, Mei Mei ^a,b   Addepalli, Balasubrahmanyam ^c   Tu, Mei Juan ^a   Chen, Qiu Xia ^a,d   Wang, Wei Peng ^a   Limbach, Patrick A ^c   Lasalle, Janine M ^a   Zeng, Su ^d   Huang, Min ^b   Yu, Ai Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF CINCINNATI   (United States)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; METHYL CPG BINDING PROTEIN 2; MICRORNA 1291; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; RECOMBINANT RNA; SEPHADEX; TRANSFER RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FOXA2 PROTEIN, HUMAN; MECP2 PROTEIN, HUMAN; MICRORNA; MIRN1291 MICRORNA, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; RECOMBINANT DNA;

ABCC1 GENE; AFFINITY CHROMATOGRAPHY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; FOXA2 GENE; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MECP2 GENE; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CARCINOMA; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PLASMID; PROTEIN ENGINEERING; TUMOR CELL LINE;

ESCHERICHIA COLI;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DNA, RECOMBINANT; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HUMANS; METHYL-CPG-BINDING PROTEIN 2; MICRORNAS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLASMIDS; PROTEIN ENGINEERING;

EID: 84940387756     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.064493     Document Type: Article

References (43)

1. Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, and Phizicky EM (2006) Rapid tRNA decay can result from lack of nonessential modifications. Mol Cell 21: 87-96.
2. Bader AG, Brown D, and Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70:7027-7030.
3. Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, and Yu AM (2014) N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis 35:2264-2272.
4. Billard LM, Magdinier F, Lenoir GM, Frappart L, and Dante R (2002) MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland. Oncogene 21:2704-2712.
5. Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, and Kaestner KH (2008) Hepatocytespecific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med 14:828-836.
6. Bochkis IM, Schug J, Ye DZ, Kurinna S, Stratton SA, Barton MC, and Kaestner KH (2012) Genome-wide location analysis reveals distinct transcriptional circuitry by paralogous regulators Foxa1 and Foxa2. PLoS Genet 8:e1002770.
7. Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, Vendeix FA, Fabris D, and Agris PF (2011) The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res 39:D195-D201.
8. Chen QX, Wang WP, Zeng S, Urayama S, and Yu AM (2015) A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res 43:3857-3869.
9. Choi YH and Yu AM (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793-807.
10. El-Osta A and Wolffe AP (2001) Analysis of chromatin-immunopurified MeCP2-associated fragments. Biochem Biophys Res Commun 289:733-737.
11. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Noske A, Weichert W, and Buckendahl AC, et al. (2009) Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology 54:657-666.
12. Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, and Kubista E, et al. (2005) Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23:1161-1168.
13. Gao N, LeLay J, Vatamaniuk MZ, Rieck S, Friedman JR, and Kaestner KH (2008) Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev 22:3435-3448.
14. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, and Norris MD (2006) Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24:1546-1553.
15. Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, Bruhn O, Remmler C, and Cascorbi I (2011) Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol 80:314-320.
16. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, Fuse M, Nakagawa M, and Enokida H (2012) Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3:44-57.
17. Hossain M and Limbach PA (2007) Mass spectrometry-based detection of transfer RNAs by their signature endonuclease digestion products. RNA 13:295-303.
18. Hossain M and Limbach PA (2009) Multiple endonucleases improve MALDI-MS signature digestion product detection of bacterial transfer RNAs. Anal Bioanal Chem 394:1125-1135.
19. Krivos KL, Addepalli B, and Limbach PA (2011) Removal of 39-phosphate group by bacterial alkaline phosphatase improves oligonucleotide sequence coverage of RNase digestion products analyzed by collision-induced dissociation mass spectrometry. Rapid Commun Mass Spectrom 25:3609-3616.
20. LaSalle JM and Yasui DH (2009) Evolving role of MeCP2 in Rett syndrome and autism. Epigenomics 1:119-130.
21. Li MM, Wang WP, Wu WJ, Huang M, and Yu AM (2014) Rapid production of novel premicroRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos 42:1791-1795.
22. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, and Yu AM (2011) Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 81:783-792.
23. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, and Scala S, et al. (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79: 817-824.
24. Limbach PA, Crain PF, and McCloskey JA (1994) Summary: The modified nucleosides of RNA. Nucleic Acids Res 22:2183-2196.
25. Lin X and Nelson WG (2003) Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res 63:498-504.
26. Liu Y, Stepanov VG, Strych U, Willson RC, Jackson GW, and Fox GE (2010) DNAzymemediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli. BMC Biotechnol 10:85.
27. Markova SM and Kroetz DL (2014) ABCC4 is regulated by microRNA-124a and microRNA- 506. Biochem Pharmacol 87:515-522.
28. Nelissen FH, Leunissen EH, van de Laar L, Tessari M, Heus HA, and Wijmenga SS (2012) Fast production of homogeneous recombinant RNA-towards large-scale production of RNA. Nucleic Acids Res 40:e102.
29. Pan YZ, Morris ME, and Yu AM (2009) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75: 1374-1379.
30. Pan YZ, Zhou A, Hu Z, and Yu AM (2013) Small nucleolar RNA-derived microRNA hsa-miR- 1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 41:1744-1751.
31. Pomerantz SC and McCloskey JA (1990) Analysis of RNA hydrolyzates by liquid chromatography-mass spectrometry. Methods Enzymol 193:796-824.
32. Ponchon L, Beauvais G, Nonin-Lecomte S, and Dardel F (2009) A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc 4:947-959.
33. Ponchon L and Dardel F (2007) Recombinant RNA technology: The tRNA scaffold. Nat Methods 4:571-576.
34. Ray BK, Dhar S, Henry C, Rich A, and Ray A (2013) Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family. Cancer Res 73:736-744.
35. Russell SP and Limbach PA (2013) Evaluating the reproducibility of quantifying modified nucleosides from ribonucleic acids by LC-UV-MS. J Chromatogr B Analyt Technol Biomed Life Sci 923-924:74-82.
36. Song Y, Washington MK, and Crawford HC (2010) Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70:2115-2125.
37. Taucher M and Breuker K (2010) Top-down mass spectrometry for sequencing of larger (up to 61 nt) RNA by CAD and EDD. J Am Soc Mass Spectrom 21:918-929.
38. To KK, Zhan Z, Litman T, and Bates SE (2008) Regulation of ABCG2 expression at the 39 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 28:5147-5161.
39. Trang P, Weidhaas JB, and Slack FJ (2008) MicroRNAs as potential cancer therapeutics. Oncogene 27 (Suppl 2):S52-S57.
40. Wong SY, Javid B, Addepalli B, Piszczek G, Strader MB, Limbach PA, and Barry CE 3rd (2013) Functional role of methylation of G518 of the 16S rRNA 530 loop by GidB in Mycobacterium tuberculosis. Antimicrob Agents Chemother 57:6311-6318.
41. Yamasaki T, Seki N, Yoshino H, Itesako T, Yamada Y, Tatarano S, Hidaka H, Yonezawa T, Nakagawa M, and Enokida H (2013) Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Sci 104:1411-1419.
42. Yu AM, Pan YZ, and Qiu JX (2013) Therapeutic indications of miR-1291. Internationalpatent PCT/US2013/021307.
43. Zhang Y, Ali TZ, Zhou H, D'Souza DR, Lu Y, Jaffe J, Liu Z, Passaniti A, and Hamburger AW (2010) ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res 70:240-248.